Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
相关临床试验
32
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
11
34.4%
已完成
11
34.4%
No Longer Available
1
3.1%
招募中
7
21.9%
终止
2
6.3%
暂无批准数据
- Olema Oncology has appointed Jason O'Byrne, MBA, as Chief Financial Officer as the company approaches pivotal data from its OPERA-01 study and a potential first commercial launch. - O'Byrne joins from Vir Biotechnology, where he served as Executive Vice President and CFO, and previously held CFO roles at Caribou Biosciences and Audentes Therapeutics. - His background spans corporate strategy, capital markets, business development, and financial management, including leadership of Caribou's IPO and the $3 billion Astellas acquisition of Audentes. - Olema highlighted its strong balance sheet as it advances palazestrant (OP-1250) and OP-3136 toward multiple upcoming milestones in breast cancer and beyond.
- Evercore ISI analyst Cory Kasimov reiterated a Buy rating on Vir Biotechnology with a $22.00 price target, citing the company's healthcare sector potential. - Barclays analyst Etzer Darout also maintained a Buy rating with a more bullish $30.00 price target, reflecting continued confidence in the firm's pipeline. - Vir Biotechnology reported a GAAP net loss of $125.7 million for the quarter ending March 31, compared to a $120.97 million loss in the same period last year. - The company holds an analyst consensus of Strong Buy with a consensus price target of $21.50, despite revenue declining to $3.03 million from the prior year.
- Vir Biotechnology is expected to report Q2 2026 earnings on August 5, with analysts forecasting EPS of $0.33 and revenue of $135.88 million. - The company's prior quarter (Q1 2026) saw a significant miss, reporting ($0.85) EPS against a consensus estimate of ($0.01), with revenue of ($0.03) million. - Wall Street maintains a consensus "Moderate Buy" rating with an average price target of $20.88, though one analyst has downgraded the stock to "Sell." - The clinical-stage immunology company's pipeline targets influenza A, COVID-19, HIV, hepatitis B, and tuberculosis using monoclonal antibody and immunomodulatory platforms.
- Researchers identified "Methylation Mesa" as functional regulatory elements that can be leveraged for targeted gene activation. - The work was supported by the National Research Foundation Singapore and Singapore Ministry of Education under its Research Centres of Excellence initiative. - The study involved collaborators from the Cancer Science Institute of Singapore and the Functional Genomics Consortium, including AbbVie, Bristol Myers Squibb, Janssen, Merck, and Vir Biotechnology. - The findings advance understanding of DNA methylation-based regulatory mechanisms with potential implications for epigenetic therapeutic strategies.
- Vir Biotechnology appointed Timothy Coughlin, former CFO of Neurocrine Biosciences, to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. - Coughlin brings extensive experience guiding companies from clinical-stage to fully integrated commercial enterprises, including navigating regulatory setbacks. - The appointment comes as Vir advances its potential best-in-class treatment for chronic hepatitis delta and its pipeline of masked T-cell engagers for solid tumors. - Coughlin currently serves on the boards of aTyr Pharma, ADC Therapeutics, and Travere Therapeutics, and previously served on boards including Fate Therapeutics and Peloton Therapeutics.
- Vir Biotechnology will present complete Week 96 data from the Phase 2 SOLSTICE trial evaluating tobevibart and elebsiran combination therapy for chronic hepatitis delta at EASL Congress 2026. - The oral presentation has been selected for inclusion in "Best of EASL 2026" by the European Association for the Study of the Liver. - Chronic hepatitis delta is the most severe form of chronic viral hepatitis with no approved treatments in the U.S. and limited options globally. - The investigational combination therapy targets multiple points in the hepatitis delta virus life cycle through monthly subcutaneous injections.
- Astellas and Vir Biotechnology announced a global strategic collaboration to co-develop and co-commercialize VIR-5500, a dual-masked PSMA-targeting T-cell engager for prostate cancer treatment. - The partnership includes $335 million in upfront and near-term payments to Vir, plus up to $1.37 billion in additional development, regulatory and sales milestones. - VIR-5500 utilizes PRO-XTEN masking technology designed to keep T-cell engagers inactive until reaching the tumor microenvironment, potentially reducing off-target effects. - The collaboration addresses significant unmet medical need in metastatic castration-resistant prostate cancer, which has a 5-year survival rate of approximately 30%.
- Tango Therapeutics appointed Dr. Malte Peters as President and CEO, replacing founding CEO Dr. Barbara Weber who transitions to Executive Chair. - The leadership change comes as the company's lead PRMT5 inhibitor vopimetostat prepares to enter registrational trials for pancreatic cancer in 2026. - Dr. Peters brings extensive late-stage clinical development experience, having previously led global regulatory approval of Monjuvi at MorphoSys AG. - The company maintains its 2026 clinical milestone guidance, including combination trial data and pivotal study initiation for vopimetostat.
- Vir Biotechnology granted Norgine exclusive commercial rights to tobevibart and elebsiran combination therapy for chronic hepatitis delta in Europe, Australia, and New Zealand for €55 million upfront and up to €495 million in milestones. - The combination therapy achieved 66% hepatitis delta virus RNA target not detected in Phase 2 SOLSTICE trial, representing a potentially first-of-its-kind treatment for the most severe form of chronic viral hepatitis. - Norgine will contribute 25% of ongoing ECLIPSE registrational program costs, while Vir retains commercialization rights in the United States and extends cash runway into Q4 2027.
- Brii Biosciences published Phase 2 ENSURE study results in Nature Medicine showing elebsiran combined with pegylated interferon alfa achieved HBsAg loss rates up to 33.3% compared to 5.6% with interferon monotherapy. - The study demonstrated that patients previously treated with therapeutic vaccine BRII-179 who developed anti-HBs responses had significantly higher HBsAg loss rates of 42.1% versus 8.3% in non-responders. - The combination therapy was generally safe and well-tolerated, with findings suggesting BRII-179 may prime the immune system for improved responsiveness to subsequent curative treatments.
